Abbott's AFib breakthroughs show 84% success with Volt PFA and TactiFlex Duo
Abbott's AFib breakthroughs show 84% success with Volt PFA and TactiFlex Duo
Abbott's AFib breakthroughs show 84% success with Volt PFA and TactiFlex Duo
Abbott has unveiled new clinical findings on its minimally invasive treatments for atrial fibrillation (AFib) at the AF Symposium in Boston. The results highlight strong performance from two key devices: the Volt PFA System and the TactiFlex Duo Ablation Catheter. Both therapies showed significant improvements in patient outcomes and quality of life.
The Volt PFA System received both FDA approval and CE Mark certification, allowing commercial use in the US and expanded rollout across Europe. Clinical trials reported an 84.2% success rate for treating Paroxysmal AFib (PAF) and a 67.7% success rate for Persistent AFib (PersAF) after 12 months. Patients also required fewer therapy applications—an average of 4.6 per vein—compared to competing systems. Only 5.8% of those treated needed a repeat procedure, and quality-of-life scores jumped from 63.6 to 91.4 for PAF patients and from 64.2 to 91.4 for PersAF patients.
The TactiFlex Duo Ablation Catheter, designed for focal ablation with a dual-energy platform, achieved an 81% success rate in treating PAF at six months in the FOCALFLEX Global CE Mark trial. This device allows physicians to adjust therapy based on individual patient needs and anatomy. Quality-of-life scores for patients using this catheter improved from 64.4 to 86.4 following treatment.
Abbott will also present late-breaking data on its Amulet device on Friday, February 6, between 5:30 and 7 p.m. Eastern. The findings come from the VERITAS Amulet 360 Pivotal Study, adding to the company's growing body of research in AFib treatment. As of early 2026, the Volt PFA System study has enrolled data from 45 medical centres worldwide, including sites in Japan, Australia, and the Middle East.
The latest results confirm the Volt PFA System's regulatory approval and commercial launch in key markets. Both it and the TactiFlex Duo Ablation Catheter have demonstrated high success rates, fewer repeat procedures, and marked improvements in patient well-being. Abbott's upcoming presentation on the Amulet device will provide further insights into its expanding AFib treatment portfolio.
Russia's Arctic military buildup sparks Cold War-level fears in the West
Moscow's strategic moves in the High North revive Cold War tensions. Can Britain and its allies close the defence gaps before it's too late?
Decades-Old Death Certificate Altered Ahead of Ex-Cop's Murder Trial
A 38-year-old mystery takes a stunning turn as officials rewrite history. Could this change finally bring justice for Sandra Birchmore and her unborn child?
Stair falls remain a silent epidemic with life-altering consequences
One wrong step can change a life forever. From shattered hips to brain injuries, stair falls leave lasting scars—especially for kids and seniors.
How Magnetic Storms Secretly Affect Your Health and Mood
Your headaches, sleepless nights, or sudden irritability might not be random. Magnetic storms could be silently disrupting your body—and experts reveal how to fight back.